In a stratergic move within the healthcare and biotechnology sectors, Evexia Lifecare Limited has entered into a transformative agreement with Diponed Bio Pvt Ltd, a leading innovator in regenerative medicine. The two companies signed a term sheet on November 8, 2024, marking Evexia Lifecare acquisition of a 65% stake in Diponed Bio. This strategic investment promises to fuel advancements in the biotech landscape and strengthen both companies’ positions in regenerative medicine.

Transformative Investment and Ownership

Evexia’s investment includes the purchase of 18,600 equity shares in Diponed Bio, issued on a preferential basis at Rs. 10 per share, securing them a 65% controlling interest. Alongside this acquisition, Evexia has committed an additional INR 200 million as quasi-capital to support Diponed Bio’s expansion, which will be disbursed in stages. This funding, free of interest, provides Evexia the option to convert part of it into equity if necessary to maintain its shareholding.

Advancing Regenerative Medicine

Diponed Bio is at the forefront of regenerative medicine, focusing on research and development of cell-based therapies and tissue engineering. The company’s expertise addresses critical healthcare challenges, including autoimmune diseases, degenerative conditions, and complex chronic diseases. Through innovative approaches in stem cell therapy and gene editing, Diponed Bio is working to deliver affordable, advanced solutions for conditions such as diabetic ulcers and cancer.

Strategic Benefits for Both Partners

This partnership is a strategic milestone for both Evexia and Diponed Bio. For Evexia, the deal aligns with their vision to expand into biotechnology and diversify their healthcare portfolio. The acquisition allows Evexia to enter the rapidly growing field of regenerative medicine, supporting their broader goal of addressing critical healthcare needs with accessible solutions.

On the other hand, Diponed Bio stands to benefit from Evexia’s financial backing and expertise, empowering them to enhance their R&D capabilities and scale innovative solutions for emerging markets where affordable healthcare remains a challenge.

Also Read: FICCI-EY Report Calls for ‘National Cancer Care Policy’ to Address Gaps in Access and Affordability

Building a Healthier Future

This collaboration is set to propel growth in regenerative medicine, particularly in cell-based therapies and tissue engineering. With Evexia’s support, Diponed Bio is poised to explore new partnerships and treatment options that will push the boundaries of medical innovation and make advanced, affordable therapies accessible to a wider population.

This partnership between Evexia and Diponed Bio is not only a step toward transforming healthcare but a commitment to a future where cutting-edge medical advancements are accessible to all. Together, they are poised to make a profound impact on the biotech and healthcare sectors.

Be a part of history! Express your interest and get featured in our exclusive souvenir, launching at the Bengaluru Tech Summit.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.